A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

ClinicalTrials.gov ID: NCT00246012

Public ClinicalTrials.gov record NCT00246012. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2, Multi-Center, Blinded, Randomized, Controlled Study of the Safety and Efficacy of the Human Monoclonal Antibody to Human α ν Integrins (CNTO 95), Alone and in Combination With Dacarbazine, in Subjects With Stage IV Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and effectiveness of the intetumumab, alone and in combination with dacarbazine, in patients with stage 4 melanoma.

Study identification

NCT ID: NCT00246012
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Centocor, Inc.; Industry
Enrollment: 144 participants

Conditions and interventions

Conditions

Melanoma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2005 (Type not available)
Primary completion: Jun 2008 (Actual)
Completion: Feb 2009 (Actual)
Last update posted: Aug 19, 2013

2005 – 2009

United States locations

U.S. sites: 17
U.S. states: 14
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Scottsdale	Arizona	—	—
Not listed	La Jolla	California	—	—
Not listed	Santa Monica	California	—	—
Not listed	Walnut Creek	California	—	—
Not listed	Aurora	Colorado	—	—
Not listed	Washington D.C.	District of Columbia	—	—
Not listed	Miami	Florida	—	—
Not listed	Atlanta	Georgia	—	—
Not listed	Park Ridge	Illinois	—	—
Not listed	Beech Grove	Indiana	—	—
Not listed	Omaha	Nebraska	—	—
Not listed	Buffalo	New York	—	—
Not listed	New York	New York	—	—
Not listed	Philadelphia	Pennsylvania	—	—
Not listed	Nashville	Tennessee	—	—
Not listed	Dallas	Texas	—	—
Not listed	Seattle	Washington	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00246012, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 19, 2013 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00246012 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →